Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors

BACKGROUND: Combinatorial inhibition of epidermal growth factor receptor (EGFR) and BRAF shows remarkable clinical benefits in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). However, the tumor may inevitably develop resistance to the targeted therapy, thereby limiting the respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ting, Wang, Xicheng, Wang, Zhenghang, Deng, Ting, Qi, Changsong, Liu, Dan, Li, Yanyan, Ji, Congcong, Li, Jian, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210093/
https://www.ncbi.nlm.nih.gov/pubmed/35747165
http://dx.doi.org/10.1177/17588359221105022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210093/
https://www.ncbi.nlm.nih.gov/pubmed/35747165
http://dx.doi.org/10.1177/17588359221105022

Ejemplares similares